Optimizing topical combination therapy for the treatment of acne vulgaris

Journal of Drugs in Dermatology

Volumn 11, Issue 3, 2012, Pages 313-317

  Zeichner, Joshua A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOYL PEROXIDE; BENZOYL PEROXIDE PLUS CLINDAMYCIN; MICROSPHERE; RETINOIC ACID;

ACNE VULGARIS; BURNING SENSATION; DRUG EFFICACY; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; ERYTHEMA; HUMAN; IN VITRO STUDY; INFLAMMATION; PROPIONIBACTERIUM ACNES; REVIEW; RISK REDUCTION; SKIN ABRASION; SKIN IRRITATION;

ACNE VULGARIS; ADMINISTRATION, CUTANEOUS; ANTI-BACTERIAL AGENTS; BENZOYL PEROXIDE; CLINDAMYCIN; DERMATOLOGIC AGENTS; HUMANS; PROPIONIBACTERIUM ACNES; RETINOIDS;

EID: 84858682253     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Gollnick, H. Current concepts of the pathogenesis of acne: implications for drug treatment. Drugs. 2003;63(15):1579-1596. (Pubitemid 36976140)
2. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(suppl 1):1S -37S.
3. Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009;60(suppl 5):1S-50S.
4. Weiss JS, Shavin JS. Topical retinoid and antibiotic combination therapy for acne management. J Drugs Dermatol. 2004;3(2):146-154.
5. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol. 2003;49(suppl 3):200S-210S.
6. Bikowski JB. Mechanisms of the comedolytic and anti-inflammatory properties of topical retinoids. J Drugs Dermatol. 2005;4(1):41-47.
7. Thielitz A, Sidou F, Gollnick H. Control of microcomedone formation throughout a maintenance treatment with adapalene gel, 0.1%. J Eur Acad Dermatol Venereol. 2007;21(6):747-753. (Pubitemid 46939044)
8. Liu PT, Krutzik SR, Kim J, Modlin RL. Cutting edge: all-trans retinoic acid down-regulates TLR2 expression and function. J Immunol. 2005;174(5):2467-2470. (Pubitemid 40279655)
9. Tenaud I, Khammari A, Dreno B. In vitro modulation of TLR?2, CD1d and IL-10 by adapalene on normal human skin and acne inflammatory lesions. Exp Dermatol. 2007;16(6):500-506. (Pubitemid 46845393)
10. Becherel PA, Mossalayi MD, LeGoff L, et al. Mechanism of anti-inflammatory action of retinoids on keratinocytes. Lancet. 1994;344(8936):1570-1571. (Pubitemid 24357722)
11. Thielitz A, Gollnick H. Topical retinoids in acne vulgaris: update on efficacy and safety. Am J Clin Dermatol. 2008;9(6):369-381.
12. Leyden JJ, Grossman R, Nighland M. Cumulative irritation potential of topical retinoid formulations. J Drugs Dermatol. 2008;7(suppl 8):14S-18S.
13. Zaenglein AL, Thiboutot DM. Expert committee recommendations for acne management. Pediatrics. 2006;118(3):1188-1199. (Pubitemid 46090063)
14. Leyden JJ, Shalita AR, Saatjlan GD, Sefton J. Erythromycin 2% gel in comparison with clindamycin phosphate 1% solution in acne vulgaris. J Am Acad Dermatol. 1987;16(4):822-827. (Pubitemid 17055885)
15. Eady EA, Farmery MR, Ross JI, Cove JH, Cunliffe WJ. Effects of benzoyl peroxide and erythromycin alone and in combination against antibiotic-sensitive and -resistant skin bacteria from acne patients. Br J Dermatol. 1994;131(3):331-336. (Pubitemid 24290215)
16. Leyden J, Kaidbey K, Levy SF. The combination formulation of clindamycin 1% plus benzoyl peroxide 5% versus 3 different formulations of topical clindamycin alone in the reduction of Propionibacterium acnes. An in vivo comparative study. Am J Clin Dermatol. 2001;2(4):263-266.
17. Eady EA, et al. The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin-resistant propionibacteria. Br J Dermatol. 1996;134(1):107-113. (Pubitemid 26030998)
18. Cunliffe WJ, et al. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther. 2002;24(7):1117-1133. (Pubitemid 34833234)
19. Gold LS. Fixed-combination products in the management of acne vulgaris. Cutis. 2010;85(3):160-167.
20. Seidler EM, Kimball AB. Meta-analysis of randomized controlled trials using 5% benzoyl peroxide and clindamycin versus 2.5% benzoyl peroxide and clindamycin topical treatments in acne. J Am Acad Dermatol. 2011;65(4):117-119.
21. Dosik JS, Vamvakias G. Comparative irritation potential of two combination acne products: a randomized controlled, subject-and evaluator-blind, comparative study in healthy volunteers. Am J Clin Dermatol. 2008;9(5):313-317.
22. Yan AC. Current concepts in acne management. Adolesc Med Clin. 2006;17(3):613-637. (Pubitemid 44499171)
23. Shroot B. Further light is shed on topical therapy. J Invest Dermatol. 2003;121(3):xiii-xiv.
24. Del Rosso JQ, Pillai R, Moore R. Absence of degradation of tretinoin when benzoyl peroxide is combined with an optimized formulation of tretinoin gel (0.05%). J Clin Aesthet Dermatol. 2010;3(10):26-28.
25. Feldman SR, Chen DM. How patients experience and manage dryness and irritation from acne treatment. J Drugs Dermatol. 2011;10(6):605-608.
26. Mills OH Jr, Kligman AM, Pochi P, Comite H. Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol. 1986;25(10):664-667. (Pubitemid 17210594)
27. Dosik JS, Vamvakias G. Comparative irritation potential of two combination acne products: a randomized controlled, subject- and evaluator-blind, comparative study in healthy volunteers. Am J Clin Dermatol. 2008;9(5):313-317.
28. Banker GS, Christopher TR, eds. Modern Pharmceutics. 4th ed. New York, NY: Marcel Dekker; 2002.
29. Bucks D, Sarpotdar P, Yu K, Angel A, Del Rosso J. The development and optimization of a fixed combination of clindamycin and benzoyl peroxide aqueous gel with minimal irritation and enhanced bioavailability. J Drugs Dermatol. 2009;8(7):634-638.
30. Torok H, Pillai R. Safety and efficacy of micronized tretinoin gel (0.05%) in treating adolescent acne. J Drugs Dermatol. 2011;10(6):647-652.
31. Tabbakhian M, Sharifian A, Shatalebi MA. Preparation and in vitro characterization of tretinoin-containing microspheres suited for dermatological preparations. Res Pharma Sci. 2008;3(2):31-40.
32. Erden N, Celebi N. Factors influencing release of salbutamol sulphate from poly (lactide-co-glycolide) microspheres prepared by water-in-oil-inwater emulsion technique. Int J Pharm. 1996;137(1):57-66. (Pubitemid 26238512)
33. Chu I, Dick D, Bronaugh R, Tryphonas L. Skin reservoir formation and bioavailability of dermally administered chemicals in hairless guinea pigs. Food Chem Toxicol. 1996;34(3):267-276. (Pubitemid 26104663)
34. Lampen P, Pittermann W, Heise HM, Schmitt M, Jungmann H, Kietzmann M. Penetration studies of vitamin E acetate applied from cosmetic formulations to the stratum corneum of an in vitro model using quantification by tape stripping, UV spectroscopy, and HPLC. J Cosmet Sci. 2003;54(2):119-131. (Pubitemid 36618643)
35. Toll R, Jacobi U, Richter H, Lademann J, Schaefer H, Blume-Peytavi U. Penetration profile of microspheres in follicular targeting of terminal hair follicles. J Invest Dermatol. 2004;123(1):168-176. (Pubitemid 38833478)
36. Del Rosso JQ, et al. Absence of degradation of tretinoin when benzoyl peroxide is combined with an optimized formulation of tretinoin gel (0.05%). J Clin Aesthet Dermatol. 2010;3(10):26-28.
37. Del Rosso JQ, Harper J, Pillai R, Moore R. Tretinoin photostability: comparison of micronized tretinoin (0.05%) gel and tretinoin (0.025%) gel following exposure to ultraviolet a light. J Clin Aesthet Dermatol. 2012;5(1):27-29.
38. Thiboutot D, Zaenglein A, Weiss J, Webster G, Calvarese B, Chen D. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. J Am Acad Dermatol. 2008;59(5):792-800.
39. Bikowski J. Rediscovering topical antimicrobial therapy for acne vulgaris. Practical Dermatology. 2009;6(4):55-58.
40. Gold MH. A new, once-daily, optimized, fixed combination of clindamycin phosphate 1.2% and low-concentration benzoyl peroxide 2.5% gel for the treatment of moderate-to-severe acne. J Clin Aesthetic Dermatol. 2009;2(5):44-48.
41. Cook-Bolden F. Clindamycin phosphate 1.2% and benzoyl peroxide 2.5%: a new, once-daily, fixed combination treatment for moderate to severe acne. Cosmet Dermatol. 2009;22(6):319-322.
42. Webster G, Rich P, Gold MH, Mraz S, Calvarese B, Chen D. Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. J Drugs Dermatol. 2009;8(8):736-743.
43. Novel fixed-combination clindamycin phosphate and low-concentration benzoyl peroxide formulation shows efficacy, tolerability. Practical Dermatology for Pediatricians. 2010;1(2);6-7.
44. Del Rosso JQ. Topical management of acne vulgaris using a combination gel formulation: benzoyl peroxide 2.5%-clindamycin phosphate 1.2% gel. Expert Review of Dermatology. 2010;5(6):597-603.
45. Webster G, Cargill DI, Quiring J, Vogelson CT, Slade HB. A combined analysis of 2 randomized clinical studies of tretinoin gel 0.05% for the treatment of acne. Cutis. 2009;83(3):146-154.
46. Lucky AW, Cullen SI, Funicella T, et al. Double- blind, vehicle-controlled, multicenter comparison of two 0.025% tretinoin creams in patients with acne vulgaris. J Am Acad Dermatol. 1998;38(4) (suppl):24S-30S.
47. Lucky AW, Cullen SI, Jarratt MT, et al. Comparative efficacy and safety of two 0.025% tretinoin gels: results from a multicenter double-blind, parallel study. J Am Acad Dermatol. 1998;38(4) (suppl): 17S-23S.
48. Lucky AW, Sugarman J. Comparison of micronized tretinoin gel 0.05% and tretinoin gel microsphere 0.1% in young adolescents with acne: a post-hoc analysis of efficacy and tolerability data. Cutis. 2011;87(6):305-310.